Last reviewed · How we verify
BSI-045B
At a glance
| Generic name | BSI-045B |
|---|---|
| Sponsor | Biosion, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis (PHASE2)
- Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BSI-045B CI brief — competitive landscape report
- BSI-045B updates RSS · CI watch RSS
- Biosion, Inc. portfolio CI